Trajectory and mortality of Preserved Ratio Impaired Spirometry: the Rotterdam Study

S. R. A. Wijnant^{1,2,3}, E. De Roos^{1,2}, M. Kabousi², B. H. Stricker^{2,4}, N. Terzikhan², L. Lahousse^{2,3*}, G. G. Brusselle^{1,2,5*}

¹Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium;

²Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands;

³Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium;

- ⁴Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands;
- ⁵Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

*These authors supervised the work equally.

Corresponding author:

Guy Brusselle Department of Respiratory medicine, University Hospital Ghent Corneel Heymanslaan 10 9000 Ghent, Belgium guy.brusselle@ugent.be

Supplementary files

Tables

- 1. Representativeness of the study subjects with follow-up data.
- 2. Lung function values at phase 1 and phase 2 stratified by lung function category and smoking status at phase 2.
- 3. Characteristics at phase 1 by lung function category at phase 1 and phase 2.
- 4. Lung function values at phase 1 and phase 2 up stratified by lung function category at phase 1 and phase 2.
- 5. ICD10 classification of cause-specific mortality.
- 6. Estimates of mortality stratified by lung function categories.

Figures

- 1. Flowchart of the Rotterdam Study.
- 2. Age- and sex-specific prevalence, incidence and mortality of PRISm and COPD.
- Transitions between lung function categories according to LLN definitions for FEV₁ and the FEV₁/FVC ratio.

Table S1. Representativeness of the study subjects with follow-up data.

	Characteristics at phase	1 of the subgroup with foll	ow-up at phase 2 (n=1603)	Characteristics at phase	Characteristics at phase 1 of the subgroup without follow-up at phase 2 (n=1254			
	Normal-P1 (n=1276)	PRISm-P1 (n=89)	COPD-P1 (n=238)	Normal-P1 (n=856)	PRISm-P1 (n=121)	COPD-P1 (n=277)		
Age (years)	73.7 (4.9)	74.7 (5.7)	74.3 (5.0)	77.8 (6.1)*	78.2 (6.3)*	78.4 (6.1)*		
Female sex	729 (57.1)	51 (57.3)	106 (44.5)	523 (61.1)	64 (52.9)	126 (45.5)		
BMI (kg/m²)	27.6 (4.1)	29.1 (3.8)	26.6 (3.9)	27.7 (4.1)	28.7 (5.0)	26.3 (3.8)		
Current smoker	85 (6.7)	6 (6.7)	29 (12.2)	55 (6.4)	20 (16.5)	77 (27.8)*		
Pack-years (years)	3.2 (0.0, 18.8)	10.8 (0.0, 29.0)	19.8 (1.7, 40.4)	2.3 [0.0, 21.0]	11.3 [0.0, 30.0]	22.8 [5.2, 42.0]		
White blood cell count	6.8 (1.7)	7.5 (1.8)	7.2 (1.7)	7.0 (1.8)	7.4 (1.9)	7.9 (3.2)		
Diabetes mellitus	97 (7.7)	6 (6.8)	21 (9.1)	79 (9.7)	10 (8.9)	28 (10.3)		
Hypertension	1065 (83.5)	80 (89.9)	202 (84.9)	757 (88.5)*	115 (95.0)	240 (86.6)		
Heart failure	34 (2.7)	4 (4.5)	11 (4.6)	47 (5.5)*	22 (18.3)*	34 (12.3)*		
Coronary heart disease	123 (9.7)	12 (13.5)	33 (13.9)	103 (12.1)	21 (17.5)	47 (17.0)		
FEV ₁ % predicted (%)	104.8 (13.8)	72.6 (6.4)	77.9 (17.8)	104.3 (14.0)	70.4 (8.6)*	72.4 (18.1)*		
FVC% predicted (%)	101.9 (13.2)	72.7 (7.6)	92.6 (16.7)	100.7 (13.9)*	69.7 (9.9)*	87.0 (17.6)*		
FEV ₁ /FVC (%)	78.6 (4.7)	76.3 (5.1)	63.5 (6.7)	78.8 (4.9)	76.8 (5.0)	62.4 (7.1)		
DLCO (mmol/min/kPA)	7.5 (1.5)	7.2 (1.4)	7.2 (1.7)	7.1 (1.4)*	7.1 (1.6)	6.5 (1.5)*		
DLCO/VA (mmol/min/kPA)	1.5 (0.2)	1.6 (0.2)	1.4 (0.3)	1.5 (0.2)*	1.5 (0.3)*	1.3 (0.3)*		
Deaths before P2 (%)	NA	NA	NA	223 (26.1)	46 (38.0)	100 (36.1)		

A. Characteristics of subjects from cohort 1 and 2 with and without follow-up spirometry at phase 2.

PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; BMI = body mass index; FEV_1 = Forced expiratory volume in one second; FVC = Forced vital capacity; DLCO = diffusion capacity of the lung for carbon monoxide; DLCO/VA = diffusion capacity of the lung for carbon monoxide per alveolar volume. *P<0.05 compared to subjects with follow-up. Results are presented as mean (SD), count (percentage) or median (interquartile range).

B. Characteristics of subjects from cohort 1 and 2 with follow-up and of subjects from cohort 1 and 2 with loss of follow-up at phase 2 (i.e. no follow-up

spirometry at phase 2 and no death before end of phase 2 examinations).

	Characteristics at phase	1 of the subgroup with following the subgroup with following the subgroup with following the subgroup with the subgroup	low-up at phase 2 (n=1603)	Characteristics at phase 1 of the subgroup with loss of follow-up at phase 2 (i.e.				
				no follow-up spirometry at phase 2 and no death before end of phase 2) (n=884				
	Normal-P1 (n=1276)	PRISm-P1 (n=89)	COPD-P1 (n=238)	Normal-P1 (n=633)	PRISm-P1 (n=75)	COPD-P1 (n=177)		
Age (years)	73.7 (4.9)	74.7 (5.7)	74.3 (5.0)	76.9 (5.8)*	76.4 (5.9)	77.3 (5.8)*		
Female sex	729 (57.1)	51 (57.3)	106 (44.5)	412 (65.1)*	46 (61.3)	92 (52.0)		
BMI (kg/m ²)	27.6 (4.1)	29.1 (3.8)	26.6 (3.9)	28.0 (4.2)*	29.2 (5.2)	26.5 (3.9)		
Current smoker	85 (6.7)	6 (6.7)	29 (12.2)	34 (5.4)	11 (14.7)	45 (25.4)*		
Pack-years (years)	3.2 (0.0, 18.8)	10.8 (0.0, 29.0)	19.8 (1.7, 40.4)	1.4 (0.0, 20.0)	8.0 (0.0, 25.0)	19.0 (0.3, 39.0)		
White blood cell count	6.8 (1.7)	7.5 (1.8)	7.2 (1.7)	6.9 (1.6)	7.1 (1.8)	7.6 (2.1)*		
Diabetes mellitus	97 (7.7)	6 (6.8)	21 (9.1)	59 (9.8)	4 (5.6)	18 (10.3)		
Hypertension	1065 (83.5)	80 (89.9)	202 (84.9)	558 (88.2)*	73 (97.3)	148 (83.6)		
Heart failure	34 (2.7)	4 (4.5)	11 (4.6)	25 (4.0)	9 (12.2)	11 (6.2)		
Coronary heart disease	123 (9.7)	12 (13.5)	33 (13.9)	61 (9.7)	6 (8.1)	23 (13.0)		
FEV ₁ % predicted (%)	104.8 (13.8)	72.6 (6.4)	77.9 (17.8)	104.8 (13.7)	70.9 (7.8)	74.4 (18.1)		
FVC% predicted (%)	101.9 (13.2)	72.7 (7.6)	92.6 (16.7)	101.5 (13.6)	70.6 (9.0)	88.5 (17.2)*		
FEV ₁ /FVC (%)	78.6 (4.7)	76.3 (5.1)	63.5 (6.7)	78.7 (4.7)	76.7 (5.0)	63.2 (6.4)		
DLCO (mmol/min/kPA)	7.5 (1.5)	7.2 (1.4)	7.2 (1.7)	7.2 (1.4)*	7.5 (1.4)	6.7 (1.5)*		
DLCO/VA (mmol/min/kPA)	1.5 (0.2)	1.6 (0.2)	1.4 (0.3)	1.5 (0.2)	1.5 (0.3)	1.3 (0.3)		

PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; BMI = body mass index; FEV_1 = Forced expiratory volume in one second; FVC = Forced vital capacity; DLCO = diffusion capacity of the lung for carbon monoxide; DLCO/VA = diffusion capacity of the lung for carbon monoxide per alveolar volume. *P<0.05 compared to subjects with follow-up. Results are presented as mean (SD), count (percentage) or median (interquartile range).

Table S2. Lung function values at phase 2	1 and phase 2 stratified by lung f	function category and smoking status at phase 2.

		Normal spirometry- P1(n=1276)	PRISm-P1 (n=89)	COPD GOLD1-4-P1 (n=238)	COPD GOLD1-P1(n=114)	COPD GOLD 2-4-P1 (n124)
Years betwee	en P1 and P2	4.6 (0.5)	4.6 (0.4)	4.6 (0.4)	4.6 (0.4)	4.6 (0.4)
FEV ₁ % predic	ted at P1 (%)	104.8 (13.8)	72.6 (6.4)*	77.9 (17.8)*	92.9 (9.8)*	64.1 (11.2)*
FEV ₁ % predic	ted at P2 (%)	102.0 (15.9)	72.8 (13.6)*	78.3 (19.9)*	91.5 (13.2)*	66.2 (17.2)*
$\Delta {\sf FEV}_1$	All (n=1603)	-45.0 (-75.2, -17.4)	-20.4 (-67.0, 1.9)*	-31.0 (-60.3, 4.4)*	-39.4 (-63.3, -14.1)	-21.6 (-46.9, 19.3)*
(ml/year)	Never smokers (n=534)	-46.0 (-76.4, -20.0)	-25.2 (-44.6, -2.2)	-29.7 (-56.8, 3.7)*	-32.4 (-72.1, -21.3)	-8.2 (-39.5, 15.3)*
	Former smokers (n=949)	-43.5 (-74.5, -15.8)	-16.4 (-71.5, 1.0)*	-29.9 (-58.6, 5.4)*	-37.9 (-61.9, -12.6)	-22.0 (-48.2, 25.9)*
	Current smokers (n=120)	-49.3 (-75.1, -25.3)	-19.7 (-28.6, -1.5)	-40.8 (-65.1, -15.7)	-56.1 (-85.8, -22.0)	-29.2 (-44.8, -6.7)
FVC% predict	ed at P1 (%)	101.9 (13.2)	72.7 (7.6)*	92.6 (16.8)*	105.4 (11.2)*	81.0 (11.8)*
FVC% predict	ed at P2 (%)	104.4 (15.3)	78.9 (13.5)*	97.7 (18.1)*	108.7 (15.0)*	87.6 (14.5)*
Δ FVC	All (n=1603)	-20.2 (-55.8, 20.4)	5.5 (-38.4, 59.0)*	-2.0 (-46.4, 50.2)*	-6.7 (-66.1, 34.2)	8.0 (-37.6, 65.5)*
(ml/year)	Never smokers (n=534)	-25.3 (-63.9, 10.6)	-13.4 (-37.0, 48.3)	-9.5 (-59.9, 25.1)	-16.4 (-72.0, 4.5)	-5.6 (-43.8, 29.3)
	Former smokers (n=949)	-17.6 (-53.5, 22.7)	5.7 (-45.2, 60.1)*	2.4 (-43.3, 65.5)*	-4.1 (-48.2, 53.1)	12.0 (-36.8, 81.5)*
	Current smokers (n=120)	-9.0 (-49.0, 23.8]	39.3 (12.6, 105.8)	-23.4 (-57.2, 25.3)	-42.1 (-80.3, 8.1)	7.2 (-33.5, 44.2]

PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; GOLD = Global initiative for Chronic Obstructive Lung Disease; P1 = phase 1; P2 = phase 2; FEV₁ = Forced Expiratory Volume in one second; FVC = Forced Vital Capacity; Δ = delta. *P<0.05 compared to subjects with normal spirometry. Results are presented as mean (SD) or median (interquartile range).

	Normal (n=1276)			PRISm (n=89)			COPD (n=238)			
	Normal	PRISm (n=47)	COPD (n=298)	Normal (n=14)	PRISm (n=31)	COPD (n=44)	Normal (n=25)	PRISm (n=5)	COPD (n=208)	
	(n=931)									
Years between P2 and P2	4.7 (0.5)	4.9 (0.5)	4.8 (0.5)	4.6 (0.4)	4.8 (0.4)	4.8 (0.4)	4.7 (0.3)	5.3 (0.4)	4.7 (0.4)	
Age (years)	73.3 (4.6)	75.5 (5.9)	74.6 (5.2)	72.9 (3.3)	74.9 (6.4)	75.1 (5.7)	73.7 (4.4)	80.3 (3.8)	74.3 (5.1)	
Female sex	561 (60.3)	27 (57.4)	141 (47.3)	12 (85.7)	15 (48.4)	24 (54.5)	15 (60.0)	2 (40.0)	89 (42.8)	
BMI (kg/m ²) P1	27.7 (4.2)	29.0 (4.7)	27.2 (3.7)	28.3 (3.9)	30.2 (4.1)	28.7 (3.6)	26.0 (4.3)	29.5 (4.8)	26.6 (3.8)	
BMI (kg/m ²) P2	27.5 (4.2)	29.3 (5.0)	27.0 (3.8)	28.2 (4.0)	29.7 (4.4)	28.5 (3.9)	25.9 (4.3)	27.4 (5.4)	26.3 (3.9)	
Δ BMI (kg/m ²)	-0.2 (1.6)	0.3 (1.9)	-0.1 (1.5)	-0.1 (1.1)	-0.5 (2.2)	-0.2 (1.2)	-0.02 (0.2)	-0.4 (0.9)	-0.1 (0.3)	
$\Delta BMI > 1.5 \text{ kg/m}^2$ (%)	109 (11.7)	12 (25.5)	32 (10.7)	1 (7.1)	5 (16.1)	3 (6.8)	2 (8.0)	1 (20.0)	25 (12.0)	
Waist circumference (cm) P1	92.9 (11.7)	97.2 (14.5)	92.9 (11.7)	92.8 (12.4)	101.1 (9.4)	99.1 (12.1)	88.1 (14.0)	101.6 (16.9)	94.1 (12.3)	
Waist circumference (cm) P2	94.5 (12.3)	101.4 (15.2)	95.2 (12.0)	93.4 (11.5)	101.1 (11.0)	101.1 (12.2)	90.7 (12.5)	99.1 (17.4)	95.4 (12.4)	
Δ waist circumference (cm)	1.6 (6.9)	4.2 (6.8)	2.3 (5.6)	0.6 (3.7)	-0.1 (6.8)	2.0 (6.6)	2.6 (4.8)	-2.5 (8.8)	1.3 (5.5)	
Height (cm)	166.9 (9.0)	167.1 (7.3)	169.1 (9.0)	162.5 (7.7)	167.0 (9.7)	167.9 (9.5)	166.7 (9.7)	173.6 (9.9)	170.5 (9.6)	
Current smokers	44 (4.7)	4 (8.5)	37 (12.4)	1 (7.1)	1 (3.2)	4 (9.1)	3 (12.0)	0 (0.0)	26 (12.5)	
Pack-years (years)	1.9 (0.0, 16.0)	3.0 (0.0, 20.5)	8.8 (0.0, 25.4)	0.5 (0.0, 7.1)	16.2 (0.1, 32.5)	11.2 (0.0, 30.8)	6.5 (0.5, 15.8)	16.0 (8.5, 25.0)	21.6 (2.9, 44.3)	
Total cholesterol (mmol/l)	5.5 (1.1)	5.4 (1.2)	5.3 (1.1)	5.4 (0.9)	5.0 (1.0)	5.2 (1.2)	5.2 (1.1)	5.0 (1.1)	5.4 (1.0)	
HDL-cholesterol (mmol/l)	1.5 (0.4)	1.4 (0.3)	1.5 (0.4)	1.5 (0.4)	1.4 (0.4)	1.4 (0.4)	1.6 (0.5)	1.3 (0.6)	1.5 (0.4)	
Tryglicerides (mmol/l)	1.3 (1.0, 1.7)	1.3 (1.1, 1.6)	1.2 (1.0, 1.7)	1.5 (1.1, 1.7)	1.4 (1.1, 1.9)	1.4 (1.0, 1.9)	1.1 (0.9, 1.4)	1.4 (1.1, 1.6)	1.2 (0.9, 1.6)	
Glucosis (mmol/l)	5.5 (5.1, 6.1)	5.7 (5.2, 6.5)	5.5 (5.2 <i>,</i> 6.1)	5.5 (4.9, 5.9)	5.9 (5.5 <i>,</i> 6.5)	5.5 (5.1 <i>,</i> 6.3)	5.3 (4.9 <i>,</i> 5.7)	5.7 (5.4, 6.5)	5.5 (5.1, 6.0)	
White blood cell count	6.8 (1.7)	7.0 (1.9)	6.9 (1.5)	7.1 (1.1)	7.6 (2.2)	7.5 (1.8)	7.1 (1.7)	7.1 (3.0)	7.2 (1.7)	
Diabetes mellitus	73 (8.0)	6 (12.8)	18 (6.1)	1 (7.7)	2 (6.5)	3 (6.8)	1 (4.0)	0 (0.0)	20 (9.9)	
Hypertension	775 (83.2)	40 (85.1)	250 (83.9)	13 (92.9)	29 (93.5)	38 (86.4)	23 (92.0)	5 (100.0)	174 (83.7)	
Prevalent Heart failure	25 (2.7)	1 (2.1)	8 (2.7)	0 (0.0)	2 (6.5)	2 (4.5)	0 (0.0)	0 (0.0)	11 (5.3)	
Incident Heart failure	8 (0.9)	5 (10.9)	2 (0.7)	0 (0.0)	4 (13.8)	3 (7.1)	1 (4.0)	0 (0.0)	6 (339)	
Prevalent coronary heart disease	91 (9.8)	5 (10.6)	27 (9.1)	1 (7.1)	4 (12.9)	7 (15.9)	5 (20.0)	0 (0.0)	28 (13.5)	
Incident coronary heart diease	14 (1.7)	1 (2.4)	11 (4.1)	0 (0.0)	0 (0.0)	1 (2.7)	2 (10.0)	0 (0.0)	6 (3.3)	
Deaths after P2	42 (4.5)	7 (14.6)	20 (6.7)	1 (7.1)	4 (12.9)	2 (4.5)	1 (4.0)	2 (40.0)	17 (8.2)	
Follow-up after P2 (person-years)	3135.4	157.6	1009.0	45.7	96.0	147.2	88.4	17.3	701.7	
Mortality rate per 1000 PY after P2	13.4	44.4	19.8	21.9	41.7	13.6	11.3	115.5	24.2	
Mortality rate ratio after P2	Ref	3.3	1.5	1.6	3.1	1.0	0.8	8.6	1.8	

PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; BMI = body mass index; HDL = high-density cholesterol; P1 = phase 1; P2 = phase 2. Results are presented as mean (SD), count (percentage) or median (interquartile range)

	Normal (1276)			PRISm (89)			COPD (238)		
	Normal (931)	PRISm (47)	COPD (298)	Normal (14)	PRISm (31)	COPD (44)	Normal (25)	PRISm (5)	COPD (208)
FEV1% predicted P1	107.2 (13.9)	91.5 (8.9)	99.5 (11.5)	75.5 (4.0)	72.0 (6.9)	72.1 (6.6)	86.7 (15.8)	68.9 (7.6)	77.0 (17.9)
FEV1% predicted P2	106.3 (14.1)	73.8 (5.6)	92.9 (13.8)	92.5 (12.3)	69.0 (8.9)	69.2 (11.3)	101.5 (13.5)	65.9 (8.9)	75.8 (18.9)
∆ FEV1 (ml/year)	-40.6 (-65.9, -	-104.9 (-146.6, -	-62.2 (-92.8, -	43.7 (7.7, 75.7)	-31.0 (-69.6, -	-36.7 (-74.3, -	27.1 (-22.1,	-24.9 (-86.9,	-36.2 (-64.0, -
	13.0)	73.1)	32.1)		7.7)	10.6)	106.7)	0.0)	4.1)
FVC% predicted P1	102.9 (13.4)	87.8 (8.1)	101.3 (11.9)	72.8 (5.9)	69.1 (7.4)	75.3 (7.3)	101.7 (15.8)	76.5 (6.1)	91.9 (16.6)
FVC% predicted P2	105.6 (14.3)	74.2 (7.6)	105.3 (14.6)	91.8 (11.2)	70.1 (9.9)	81.0 (12.3)	99.2 (12.9)	64.9 (8.3)	98.4 (18.1)
∆ FVC (ml/year)	-20.6 (-56.8,	-91.3 (-171.6, -	-11.9 (-40.1,	76.2 (49.5,	-20.6 (-48.9,	-11.9 (-40.1,	-51.3 (-82.6, -	-103.3 (-157.7, -	7.1 (-39.8, 56.3)
	19.3)	52.7)	51.9)	119.5)	22.2)	51.9)	8.7)	47.7)	
FEV1/FVC P1	79.8 (4.4)	79.4 (3.9)	74.7 (3.6)	80.3 (5.5)	79.7 (4.5)	72.7 (2.1)	65.0 (5.1)	67.1 (4.7)	63.2 (6.9)
FEV1/FVC P2	76.4 (4.4)	75.3 (4.8)	66.4 (2.9)	77.0 (3.5)	74.6 (3.5)	64.3 (4.0)	77.5 (5.9)	75.1 (2.2)	57.7 (8.7)
Δ FEV1/FVC (%)	-3.4 (4.5)	-4.1 (5.4)	-8.3 (4.1)	-3.3 (5.9)	-5.1 (4.7)	-8.4 (4.4)	12.5 (8.9)	8.0 (3.1)	-5.5 (5.6)
DLCO (mmol/min/kPA)	7.5 (1.5)	7.2 (1.2)	7.5 (1.5)	6.4 (1.0)	7.2 (1.2)	7.6 (1.6)	7.2 (1.1)	8.4 (1.1)	7.1 (1.8)
DLCO % predicted (%)	97.7 (13.7)	95.3 (17.1)	96.0 (14.9)	89.1 (12.5)	95.7 (22.0)	94.6 (20.0)	96.6 (9.9)	109.9 (15.9)	88.5 (19.4)
DLCO/VA	1.5 (0.2)	1.6 (0.2)	1.4 (0.2)	1.6 (0.2)	1.7 (0.3)	1.6 (0.2)	1.5 (0.2)	1.6 (0.2)	1.3 (0.3)
(mmol/min/kPA)									
DLCO/VA % predicted	112.3 (16.0)	120.7 (17.2)	109.1 (17.4)	116.6 (11.0)	125.8 (21.1)	109.1 (17.4)	110.8 (14.9)	129.6 (16.3)	102.2 (20.2)
(%)									

Table S4. Lung function values at phase 1 and phase 2 stratified by lung function category at phase 1 and phase 2.

PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; FEV_1 = Forced expiratory volume in one second; FVC = Forced vital capacity; P1 = phase 1; P2 = P2; Δ = delta; DLCO = diffusion capacity of the lung for carbon monoxide; DLCO/VA = diffusion capacity of the lung for carbon monoxide per alveolar volume. Results are presented as mean (SD) and median (interquartile range)

Table S5. Estimates of mortality stratified by lung function categories.

	Number at risk	All deaths	Follow-up (years)	Mortality rate (per 1000 PY)	Mortality rate ratio	HR [95%CI] ¹	HR [95%CI] ²	HR [95%CI] ³	HR [95%CI] ⁴	CV deaths	Follow- up (years)	Mortality rate (per 1000 PY)	Mortality rate ratio	HR [95%CI] ¹	HR [95%CI] ⁴
Total population	5446	686	35766	19.2	NA	NA	NA	NA	NA	82	15771	5.2	NA	NA	NA
		Globa	al initiative for C) bstructive I un	g Disease (GOLD) definition									
Normal	4150	425	27517	15.4	Reference	Reference	Reference	Reference	Reference	43	11973	3.6	Reference	Reference	Reference
PRISm	384	71	2441	29.1	1.9	1.6 [1.2-2.0]	1.6 [1.3, 2.1]	1.6 [1.2, 2.0]	1.6 [1.2, 2.0]	15	111	13.5	3.8	2.7 [1.5, 5.0]	2.6 [1.4, 4.7]
FEV₁≥74%	194	30	1261	23.8	1.5	1.3 [0.9, 1.8]	NP	NP	1.4 [1.0, 1.9]	7	566	12.4	3.4	2.6 [1.1, 5.7]	2.5 [1.1, 5.5]
FEV1<74%	190	41	1180	34.7	2.3	1.9 [1.4, 2.6]	NP	NP	1.7 [1.3, 2.3]	8	545	14.7	4.1	2.8 [1.3, 6.0]	2.6 [1.2, 5.7]
- FVC≥73%	191	28	1226	22.8	1.5	1.4 [1.0, 2.1]	NP	NP	1.4 [0.9, 2.0]	4	536	7.5	2.1	1.8 [0.7, 5.1]	1.7 [0.6, 4.8]
FVC<73%	193	43	1215	35.4	2.3	1.7 [1.2, 2.3]	NP	NP	1.7 [1.3, 2.3]	11	575	19.1	5.3	3.2 [1.6, 6.4]	3.1 [1.6, 6.1]
COPD GOLD1	419	52	2735	19.0	1.2	1.0 [0.7, 1.3]	1.0 [0.7, 1.3]	1.0 [0.7, 1.3]	0.7 [0.5, 0.9]	3	1187	2.5	0.7	0.5 [0.2, 1.6]	0.5 [0.1, 1.5]
COPD GOLD2-4	493	138	3073	44.9	2.9	1.7 [1.4, 2.1]	1.8 [1.4, 2.2]	1.7 [1.4, 2.1]	1.5 [1.2, 1.8]	21	1499	14.0	3.9	1.9 [1.1, 3.4]	1.8 [1.0, 3.1]
		Globa	al Lung Initiative	e definition (GLI): Lower Limit o	f Normal (LLN)									
NL	4791	541	31712	17.1	Reference	Reference	NP	NP	Reference	62	13944	4.4	Reference	Reference	Reference
PRISm	279	63	1751	36.0	2.1	1.9 [1.5, 2.5]	NP	NP	1.8 [1.4, 2.3]	9	816	11.0	2.5	2.2 [1.1, 4.5]	2.1 [1.0, 4.2]
FEV₁≥66%	139	26	847	30.7	1.8	1.2 [1.4, 2.3]	NP	NP	NP	2	364	5.5	1.3	1.8 [0.8,4.0]	NP
FEV1<66%	140	37	904	40.9	2.4	1.8 [1.4, 2.4]	NP	NP	NP	7	452	15.5	3.5	2.6 [1.5, 4.5]	NP
FVC≥69%	141	27	891	30.3	1.8	1.4 [1.0, 1.8]	NP	NP	NP	1	402	2.5	0.6	1.7 [0.8, 3.6]	NP
FVC<69%	138	36	860	41.9	4.5	1.7 [1.3, 2.2]	NP	NP	NP	8	414	19.3	4.4	3.3 [1.8, 5.9]	NP
COPD GOLD1	131	17	822	20.7	1.2	1.4 [0.8, 2.2]	NP	NP	1.1 [0.7, 1.7]	1	335	3.0	0.7	0.7 {0.1, 5.4}	NA
COPD GOLD2-4	245	65	1480	43.9	2.6	1.9 [1.5, 2.5]	NP	NP	1.6 [1.3, 2.1]	10	676	14.8	3.4	2.1 [1.0, 4.3]	2.0 [1.0, 4.2]
		Subgr	roup with spiror	metry measure	ments at both p	hase 1 and phase	2*								
Persistent NL	924	42	3135	13.4	Reference	Reference	NP	NP	NA	1	NA	NA	NA	NA	NA
Persistent PRISm	31	4	96	42.7	3.2	2.2 [0.8, 6.1]	NP	NP	NA	0	NA	NA	NA	NA	NA
Incident PRISm	52	9	174	51.5	3.8	2.4 [1.1, 4.9]	NP	NP	NA	0	NA	NA	NA	NA	NA
Persistent COPD	208	17	702	24.2	1.8	1.0 [0.6, 1.9]	NP	NP	NA	0	NA	NA	NA	NA	NA
Incident COPD	342	22	1156	19.0	1.4	0.9 [0.5, 1.5]	NP	NP	NA	0	NA	NA	NA	NA	NA

HR = Hazard Ratio; CV = cardiovascular; GOLD = Global initiative for Chronic Obstructive Lung Disease; PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; FEV₁ = Forced Expiratory volume in one second; FVC = Forced Vital Capacity; PY = person-years; NA = not applicable; NP = Not Performed; ¹ = HR adjusted for age, sex, BMI, current smoking and pack-years; ² = HR adjusted for age, sex, BMI, current smoking and pack-years; one the performed; the physician-diagnosed asthma excluded; 3 = HR adjusted for age, sex, BMI, current smoking, pack-years and cardiovascular comorbidity (heart failure and/or coronary heart disease); ⁴ = time-dependent HR adjusted for age, sex, BMI, current smoking and pack-years with lung function category at phase 2 as time varying covariate; * follow-up time start after spirometry at phase 2. Subjects with missing information for one of the covariates were excluded (n=13, of whom 6 died).

ICD10 code		Normal	PRISm	COPD
C00-D48	Neoplasms	81 (47.6%)	11 (29.7%)	38 (48.7%)
100–199	Diseases of the circulatory system	43 (25.3%)	15 (40.6%)	24 (30.8%)
F00F99	Mental and behavioural disorders	12 (7.1%)	3 (8.1%)	6 (7.7%)
R00-R99	Symptoms, signs and abnormal clinical and laboratory findings not elsewhere classified	15 (8.8%)	3 (8.1%)	2 (2.6%)
J00–J99	Diseases of the respiratory system	4 (2.3%)	4 (10.8%)	6 (7.7%)
G00–G99	Diseases of the nervous system	4 (2.3%)	1 (2.7%)	0 (0.0%)
K00–K93	Diseases of the digestive system	4 (2.3%)	0 (0.0%)	0 (0.0%)
V01-Y98	External causes of morbidity and mortality	3 (1.8%)	0 (0.0%)	1 (1.3%)
S00-T98	Injury, poisoning and certain other consequences of external causes	2 (1.2%)	0 (0.0%)	1 (1.3%)
A00-B99	Certain infectious and parasitic diseases	1 (0.6%)	0 (0.0%)	0 (0.0%)
M00-M99	Diseases of the musculoskeletal system and connective tissue	1 (0.6%)	0 (0.0%)	0 (0.0%)
	Total deaths with ICD10 code registration (until 01/01/2015)	170 (39.5%)	37 (51.4%)	78 (41.1%)
	Total deaths (until 30/06/2018)	430	72	190

ICD = International Classification Of Diseases; PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease.

Figure S1. Flowchart of the Rotterdam Study






Diagram of examination cycles of the Rotterdam Study (RS). RS-I-1 refers to the baseline examination of the original cohort (pilot phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). RS-I-2, RS-I-3, RS-I-4, RS-I-5, and RS-I-6 refer to re-examinations of the original cohort members. RS-II-1 refers to the extension of the cohort with persons in the study district that became 55 years since the start of the study or those of 55 years or over that migrated into the study district. RS-II-2, RS-II-3, and RS-II-4 refer to re-examinations of the extension cohort. RS-III-1 refers to the baseline examination of all persons aged 45 years and over living in the study district that had not been examined already (i.e., mainly comprising those aged 45–60 years). RS-III-2 refers to the first re-examination of this third cohort. Examination RS-I-4 and RS-II-2 were conducted as one project and feature an identical research program. Similarly, examinations RS-I-5, RS-II-3, and RS-III-2 share the same program items. Also, examinations RS-I-6 and RS-II-4 are conducted as one project. RS-IV-1 refers to the baseline visit of a new cohort, to be established in February 2016.





PRISm = Preserved Ratio Impaired Spirometry; COPD = Chronic Obstructive Pulmonary Disease; PY = personyears. Cumulative incidence of PRISm and COPD was calculated in a subset of individuals with spirometry at both phase 1 and phase 2, after exlusion for prevalent PRISm and COPD in the case of incident PRISm (n=1278), and after exclusion of prevalent COPD in the case of incident COPD (n=1365).

Figure S3. Transitions between lung function categories according to GLI definition for FEV_1 and the FEV_1/FVC ratio.

